Abstract 204P
Background
Ra-223 radioisotope has been reported to increase median survival in bone metastatic prostate carcinoma. The addition of Ra-223 to abiraterone was associated with an increased risk of bone fractures. There is no comprehensive data for using Ra-223 in veteran population.
Methods
We present a retrospective study of patients (pts) with bone metastatic CRPC who received standard doses of Ra-223 and other sequential therapies at VAPHS from 2014 to 2018. Pts were divided into agent orange exposure (AO) and no exposure (Non-AO). Time to study was calculated from the initiation of Ra-223. Time to skeletal related events (SRE), progression of PSA, bone metastasis and alkaline phosphatase (ALP) were calculated in months (mos) using unpaired T-test with two-tailed p value. Median survival was calculated by Kaplan Meier R log rank test.
Results
There were 34 pts with bone metastatic CRPC. 17 pts (50%) were AO, 17 pts (50%) Non-AO. The mean age of diagnosis of AO was 62 y/o and Non-AO was 69 y/o (p 0.005). The mean Gleason score for AO was 8.12 and Non-AO was 8.00 (p 0.7048). The median number of Ra-223 cycles was 6 (60%). 10 pts received Ra-223 as first line (29%) and 24 pts received Ra-223 later (71%). There were 12 SRE with median survival of 15 mos. There was no difference in mean time to SRE between AO (8 pts, 10.63 mos) and Non-AO (4 pts, 10.25 mos) with p 0.9306. The mean time to PSA progression for AO was 5.40 mos and Non-AO was 6.79 mos (p 0.2808). Mean time to bone progression for AO was 7.56 mos and Non-AO was 10.14 mos (p 0.1574). Mean time to ALP progression for AO and Non-AO was 6.25 mos and 8.71 mos respectively (p 0.0512). 20 patients (58%) had died. Median survival for Ra-223 first was 32 mos and for Ra-223 later was 15 mos with p 0.14 and HR 0.48 (95% CI, 0.17 to 1.3). Median survival between AO and Non-AO was 12 mos and 18 mos respectively with p 0.15 and HR 2.0 (95% CI, 0.77 to 5).
Conclusions
There is no statistical difference between AO and Non-AO in terms of time to SRE, PSA, bone and ALP progression even though there is a trend of shorter duration in AO veterans. There is no median survival difference between Ra-223 first versus Ra-223 later as well as between AO and Non-AO but there is a trend of worse survival in AO veterans.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
427P - Sahai: A restorative support to address unmet needs of women with cancer – impact on quality of life
Presenter: Poonam Maurya
Session: Poster display session
Resources:
Abstract
428P - A pilot study on comparative efficacy of tramadol or eutectic mixture of local anaesthetics (prilocaine plus lignocaine) in preventing bone marrow aspiration associated pain
Presenter: Bipinesh Sansar
Session: Poster display session
Resources:
Abstract
429P - Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events
Presenter: Sung Yong Oh
Session: Poster display session
Resources:
Abstract
430P - Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis
Presenter: Koichi Matsuo
Session: Poster display session
Resources:
Abstract
431P - An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue
Presenter: Ning Yi Yap
Session: Poster display session
Resources:
Abstract
432P - Chemotherapy induced extravasation: Incidence and possible predictors
Presenter: Shalaka Somayaji
Session: Poster display session
Resources:
Abstract
433P - Prospective outcomes of adolescent and young adult (AYA) patients received treatment from a tertiary cancer hospital in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: Poster display session
Resources:
Abstract
434P - Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases
Presenter: Sawako Kaku
Session: Poster display session
Resources:
Abstract
435P - Telephonic communication in palliative care for better management of terminal cancer patients in rural India: An NGO based approach
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists
Presenter: Frederic Ivan Ting
Session: Poster display session
Resources:
Abstract